Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Athersys stock

Own Athersys stock in just a few minutes.

Athersys, Inc is a biotechnology business based in the US. Athersys shares (ATHX) are listed on the NASDAQ and all prices are listed in US Dollars. Athersys employs 97 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Athersys

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATHX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Athersys share price

Use our graph to track the performance of ATHX stocks over time.

Athersys shares at a glance

Information last updated 2021-04-30.
52-week range$1.53 - $3.39
50-day moving average $1.79
200-day moving average $1.92
Wall St. target price$5.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.31

Buy Athersys shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Athersys stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Athersys financials

Revenue TTM $1.4 million
Gross profit TTM $-61,554,000
Return on assets TTM -96.58%
Return on equity TTM -288.34%
Profit margin 0%
Book value $0.16
Market capitalisation $364.8 million

TTM: trailing 12 months

Shorting Athersys shares

There are currently 26.0 million Athersys shares held short by investors – that's known as Athersys's "short interest". This figure is 0.1% down from 26.0 million last month.

There are a few different ways that this level of interest in shorting Athersys shares can be evaluated.

Athersys's "short interest ratio" (SIR)

Athersys's "short interest ratio" (SIR) is the quantity of Athersys shares currently shorted divided by the average quantity of Athersys shares traded daily (recently around 2.8 million). Athersys's SIR currently stands at 9.16. In other words for every 100,000 Athersys shares traded daily on the market, roughly 9160 shares are currently held short.

However Athersys's short interest can also be evaluated against the total number of Athersys shares, or, against the total number of tradable Athersys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athersys's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Athersys shares in existence, roughly 120 shares are currently held short) or 0.1328% of the tradable shares (for every 100,000 tradable Athersys shares, roughly 133 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Athersys.

Find out more about how you can short Athersys stock.

Athersys share dividends

We're not expecting Athersys to pay a dividend over the next 12 months.

Have Athersys's shares ever split?

Athersys's shares were split on 4 June 2007. This wouldn't directly have changed the overall worth of your Athersys shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for Athersys shares which in turn could have impacted Athersys's share price.

Athersys share price volatility

Over the last 12 months, Athersys's shares have ranged in value from as little as $1.53 up to $3.39. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athersys's is -1.674. This would suggest that Athersys's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Athersys has bucked the trend.

Athersys overview

Athersys, Inc. , a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K. K.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site